RNA logo

RNA
Avidity Biosciences Inc

1,692
Mkt Cap
$10.78B
Volume
306,853.00
52W High
$71.78
52W Low
$21.51
PE Ratio
-17.15
RNA Fundamentals
Price
$71.70
Prev Close
$71.54
Open
$71.66
50D MA
$60.20
Beta
1.29
Avg. Volume
3.99M
EPS (Annual)
-$2.89
P/B
5.57
Rev/Employee
$27,869.56
Loading...
Loading...
News
all
press releases
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to...
PR Newswire·4d ago
News Placeholder
More News
News Placeholder
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX...
PR Newswire·4d ago
News Placeholder
Guru Fundamental Report for RNA
Below is Validea's guru fundamental report for AVIDITY BIOSCIENCES INC (RNA). Of the 22 guru strategies we follow, RNA rates highest using our Small-Cap Growth Investor model based on the published...
Nasdaq News: Markets·8d ago
News Placeholder
Avidity Biosciences, Inc. $RNA Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH cut its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 56.1% in the second quarter, according to the company in its most recent...
MarketBeat·9d ago
News Placeholder
Foresite Capital Management VI LLC Makes New $1.14 Million Investment in Avidity Biosciences, Inc. $RNA
Foresite Capital Management VI LLC bought a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the second quarter, according to the company in its most recent filing...
MarketBeat·9d ago
News Placeholder
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month High - Still a Buy?
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week High - Time to Buy...
MarketBeat·10d ago
News Placeholder
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
Zacks·10d ago
News Placeholder
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
Zacks·10d ago
News Placeholder
Avidity Biosciences, Inc. $RNA Shares Sold by Intech Investment Management LLC
Intech Investment Management LLC trimmed its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 9.3% during the second quarter, according to the company in its most recent...
MarketBeat·11d ago
News Placeholder
FY2025 EPS Estimates for RNA Reduced by Cantor Fitzgerald
Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Avidity Biosciences in a report...
MarketBeat·13d ago

Latest RNA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.